Imperial College London
Portrait Picture

ProfessorGrahamWilliams

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Clinical Professor of Endocrinology
 
 
 
//

Contact

 

+44 (0)20 3313 1383graham.williams

 
 
//

Location

 

10N5Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Walsh:2021:10.1016/s2666-7568(21)00051-9,
author = {Walsh, JS and Jacques, RM and Schomburg, L and Hill, TR and Mathers, JC and Williams, GR and Eastell, R},
doi = {10.1016/s2666-7568(21)00051-9},
journal = {The Lancet Healthy Longevity},
pages = {e212--e221},
title = {Effect of selenium supplementation on musculoskeletal health in older women: a randomised, double-blind, placebo-controlled trial},
url = {http://dx.doi.org/10.1016/s2666-7568(21)00051-9},
volume = {2},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundObservational and preclinical studies show associations between selenium status, bone health, and physical function. Most adults in Europe have serum selenium below the optimum range. We hypothesised that selenium supplementation could reduce pro-resorptive actions of reactive oxygen species on osteoclasts and improve physical function.MethodsWe completed a 6-month randomised, double-blind, placebo-controlled trial. We recruited postmenopausal women older than 55 years with osteopenia or osteoporosis at the Northern General Hospital, Sheffield, UK. Participants were randomly assigned 1:1:1 to receive selenite 200 μg, 50 μg, or placebo orally once per day. Medication was supplied to the site blinded and numbered by a block randomisation sequence with a block size of 18, and participants were allocated medication in numerical order. All participants and study team were masked to treatment allocation. The primary endpoint was urine N-terminal cross-linking telopeptide of type I collagen (NTx, expressed as ratio to creatinine) at 26 weeks. Analysis included all randomly assigned participants who completed follow-up. Groups were compared with analysis of covariance with Hochberg testing. Secondary endpoints were other biochemical markers of bone turnover, bone mineral density, short physical performance battery, and grip strength. Mechanistic endpoints were glutathione peroxidase, highly sensitive C-reactive protein, and interleukin-6. This trial is registered with EU clinical trials, EudraCT 2016-002964-15, and ClinicalTrials.gov, NCT02832648, and is complete.Findings120 participants were recruited between Jan 23, 2017, and April 11, 2018, and randomly assigned to selenite 200 μg, 50 μg, or placebo (n=40 per group). 115 (96%) of 120 participants completed follow-up and were included in the primary analysis (200 μg [n=39], 50 μg [n=39], placebo [n=37]). Median follow-up was 25·0 weeks (IQR 24·7–26·0). In the 200 μ
AU  - Walsh,JS
AU  - Jacques,RM
AU  - Schomburg,L
AU  - Hill,TR
AU  - Mathers,JC
AU  - Williams,GR
AU  - Eastell,R
DO  - 10.1016/s2666-7568(21)00051-9
EP  - 221
PY  - 2021///
SN  - 2666-7568
SP  - 212
TI  - Effect of selenium supplementation on musculoskeletal health in older women: a randomised, double-blind, placebo-controlled trial
T2  - The Lancet Healthy Longevity
UR  - http://dx.doi.org/10.1016/s2666-7568(21)00051-9
UR  - https://www.sciencedirect.com/science/article/pii/S2666756821000519?via%3Dihub
UR  - http://hdl.handle.net/10044/1/88090
VL  - 2
ER  -
Download